{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "increases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uniprot:P49589",
      "entity_text" : "CARs",
      "entity_type" : "protein"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ04244",
      "entity_text" : "GD2",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "Clinical trials using T cell receptor (TCR) modified T cells seem to focus on NY-ESO-I on subtypes of sarcomas, such as liposarcoma and synovial sarcoma (NCT03450122, NCT01477021, NCT01343043, NCT03399448) while applications of Chimeric Antigen Receptor (CAR) technology in sarcoma include HER2 (NCT00902044), EGFR (NCT03618381), CD44v6 and GD2 directed CARs.",
  "reading_complete" : "2020-08-04T13:01:12Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-04T12:56:49Z",
  "trigger" : "directed",
  "evidence" : [ "GD2               directed CARs" ],
  "pmc_id" : "7001093",
  "score" : 0
}